Cargando…

Development of a High-Efficacy Reprogramming Method for Generating Human Induced Pluripotent Stem (iPS) Cells from Pathologic and Senescent Somatic Cells

Induced pluripotent stem (iPS) cells are a type of artificial pluripotent stem cell induced by the epigenetic silencing of somatic cells by the Yamanaka factors. Advances in iPS cell reprogramming technology will allow aging or damaged cells to be replaced by a patient’s own rejuvenated cells. Howev...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Naomichi, Kato, Hidemasa, Tsuda, Hiromi, Sato, Yasunori, Muramatsu, Toshihiro, Iguchi, Atsushi, Nakajima, Hiroyuki, Yoshitake, Akihiro, Senbonmatsu, Takaaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555779/
https://www.ncbi.nlm.nih.gov/pubmed/32942642
http://dx.doi.org/10.3390/ijms21186764
_version_ 1783594087030456320
author Tanaka, Naomichi
Kato, Hidemasa
Tsuda, Hiromi
Sato, Yasunori
Muramatsu, Toshihiro
Iguchi, Atsushi
Nakajima, Hiroyuki
Yoshitake, Akihiro
Senbonmatsu, Takaaki
author_facet Tanaka, Naomichi
Kato, Hidemasa
Tsuda, Hiromi
Sato, Yasunori
Muramatsu, Toshihiro
Iguchi, Atsushi
Nakajima, Hiroyuki
Yoshitake, Akihiro
Senbonmatsu, Takaaki
author_sort Tanaka, Naomichi
collection PubMed
description Induced pluripotent stem (iPS) cells are a type of artificial pluripotent stem cell induced by the epigenetic silencing of somatic cells by the Yamanaka factors. Advances in iPS cell reprogramming technology will allow aging or damaged cells to be replaced by a patient’s own rejuvenated cells. However, tissue that is senescent or pathologic has a relatively low reprogramming efficiency as compared with juvenile or robust tissue, resulting in incomplete reprogramming; iPS cells generated from such tissue types do not have sufficient differentiation ability and are therefore difficult to apply clinically. Here, we develop a new reprogramming method and examine it using myofibroblasts, which are pathologic somatic cells, from patient skin tissue and from each of the four heart chambers of a recipient heart in heart transplant surgery. By adjusting the type and amount of vectors containing transcriptional factors for iPS cell reprogramming, as well as adjusting the transfection load and culture medium, the efficiency of iPS cell induction from aged patient skin-derived fibroblasts was increased, and we successfully induced iPS cells from myocardial fibroblasts isolated from the pathologic heart of a heart transplant recipient.
format Online
Article
Text
id pubmed-7555779
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75557792020-10-19 Development of a High-Efficacy Reprogramming Method for Generating Human Induced Pluripotent Stem (iPS) Cells from Pathologic and Senescent Somatic Cells Tanaka, Naomichi Kato, Hidemasa Tsuda, Hiromi Sato, Yasunori Muramatsu, Toshihiro Iguchi, Atsushi Nakajima, Hiroyuki Yoshitake, Akihiro Senbonmatsu, Takaaki Int J Mol Sci Article Induced pluripotent stem (iPS) cells are a type of artificial pluripotent stem cell induced by the epigenetic silencing of somatic cells by the Yamanaka factors. Advances in iPS cell reprogramming technology will allow aging or damaged cells to be replaced by a patient’s own rejuvenated cells. However, tissue that is senescent or pathologic has a relatively low reprogramming efficiency as compared with juvenile or robust tissue, resulting in incomplete reprogramming; iPS cells generated from such tissue types do not have sufficient differentiation ability and are therefore difficult to apply clinically. Here, we develop a new reprogramming method and examine it using myofibroblasts, which are pathologic somatic cells, from patient skin tissue and from each of the four heart chambers of a recipient heart in heart transplant surgery. By adjusting the type and amount of vectors containing transcriptional factors for iPS cell reprogramming, as well as adjusting the transfection load and culture medium, the efficiency of iPS cell induction from aged patient skin-derived fibroblasts was increased, and we successfully induced iPS cells from myocardial fibroblasts isolated from the pathologic heart of a heart transplant recipient. MDPI 2020-09-15 /pmc/articles/PMC7555779/ /pubmed/32942642 http://dx.doi.org/10.3390/ijms21186764 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Tanaka, Naomichi
Kato, Hidemasa
Tsuda, Hiromi
Sato, Yasunori
Muramatsu, Toshihiro
Iguchi, Atsushi
Nakajima, Hiroyuki
Yoshitake, Akihiro
Senbonmatsu, Takaaki
Development of a High-Efficacy Reprogramming Method for Generating Human Induced Pluripotent Stem (iPS) Cells from Pathologic and Senescent Somatic Cells
title Development of a High-Efficacy Reprogramming Method for Generating Human Induced Pluripotent Stem (iPS) Cells from Pathologic and Senescent Somatic Cells
title_full Development of a High-Efficacy Reprogramming Method for Generating Human Induced Pluripotent Stem (iPS) Cells from Pathologic and Senescent Somatic Cells
title_fullStr Development of a High-Efficacy Reprogramming Method for Generating Human Induced Pluripotent Stem (iPS) Cells from Pathologic and Senescent Somatic Cells
title_full_unstemmed Development of a High-Efficacy Reprogramming Method for Generating Human Induced Pluripotent Stem (iPS) Cells from Pathologic and Senescent Somatic Cells
title_short Development of a High-Efficacy Reprogramming Method for Generating Human Induced Pluripotent Stem (iPS) Cells from Pathologic and Senescent Somatic Cells
title_sort development of a high-efficacy reprogramming method for generating human induced pluripotent stem (ips) cells from pathologic and senescent somatic cells
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555779/
https://www.ncbi.nlm.nih.gov/pubmed/32942642
http://dx.doi.org/10.3390/ijms21186764
work_keys_str_mv AT tanakanaomichi developmentofahighefficacyreprogrammingmethodforgeneratinghumaninducedpluripotentstemipscellsfrompathologicandsenescentsomaticcells
AT katohidemasa developmentofahighefficacyreprogrammingmethodforgeneratinghumaninducedpluripotentstemipscellsfrompathologicandsenescentsomaticcells
AT tsudahiromi developmentofahighefficacyreprogrammingmethodforgeneratinghumaninducedpluripotentstemipscellsfrompathologicandsenescentsomaticcells
AT satoyasunori developmentofahighefficacyreprogrammingmethodforgeneratinghumaninducedpluripotentstemipscellsfrompathologicandsenescentsomaticcells
AT muramatsutoshihiro developmentofahighefficacyreprogrammingmethodforgeneratinghumaninducedpluripotentstemipscellsfrompathologicandsenescentsomaticcells
AT iguchiatsushi developmentofahighefficacyreprogrammingmethodforgeneratinghumaninducedpluripotentstemipscellsfrompathologicandsenescentsomaticcells
AT nakajimahiroyuki developmentofahighefficacyreprogrammingmethodforgeneratinghumaninducedpluripotentstemipscellsfrompathologicandsenescentsomaticcells
AT yoshitakeakihiro developmentofahighefficacyreprogrammingmethodforgeneratinghumaninducedpluripotentstemipscellsfrompathologicandsenescentsomaticcells
AT senbonmatsutakaaki developmentofahighefficacyreprogrammingmethodforgeneratinghumaninducedpluripotentstemipscellsfrompathologicandsenescentsomaticcells